Thompson Siegel & Walmsley LLC lowered its stake in shares of Organon & Co. (NYSE:OGN - Free Report) by 90.8% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 208,808 shares of the company's stock after selling 2,053,571 shares during the period. Thompson Siegel & Walmsley LLC owned 0.08% of Organon & Co. worth $3,115,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
Several other hedge funds have also recently modified their holdings of OGN. Pacer Advisors Inc. grew its stake in Organon & Co. by 94,482.1% during the fourth quarter. Pacer Advisors Inc. now owns 11,152,179 shares of the company's stock valued at $166,391,000 after acquiring an additional 11,140,388 shares in the last quarter. Weiss Asset Management LP purchased a new position in shares of Organon & Co. during the third quarter valued at about $32,966,000. Jacobs Levy Equity Management Inc. grew its position in shares of Organon & Co. by 303.8% during the third quarter. Jacobs Levy Equity Management Inc. now owns 1,242,135 shares of the company's stock valued at $23,762,000 after purchasing an additional 934,505 shares in the last quarter. Charles Schwab Investment Management Inc. increased its holdings in shares of Organon & Co. by 35.7% in the third quarter. Charles Schwab Investment Management Inc. now owns 3,323,051 shares of the company's stock worth $63,570,000 after purchasing an additional 875,128 shares during the last quarter. Finally, Allspring Global Investments Holdings LLC lifted its position in shares of Organon & Co. by 191.3% in the fourth quarter. Allspring Global Investments Holdings LLC now owns 760,807 shares of the company's stock worth $11,382,000 after buying an additional 499,616 shares in the last quarter. Hedge funds and other institutional investors own 77.43% of the company's stock.
Organon & Co. Trading Up 0.5 %
NYSE OGN traded up $0.08 on Tuesday, hitting $15.70. 2,333,953 shares of the stock were exchanged, compared to its average volume of 2,340,553. The company has a debt-to-equity ratio of 17.73, a quick ratio of 1.21 and a current ratio of 1.70. Organon & Co. has a 52-week low of $13.87 and a 52-week high of $23.10. The firm has a market capitalization of $4.05 billion, a P/E ratio of 4.71, a P/E/G ratio of 0.90 and a beta of 0.76. The stock has a fifty day moving average price of $15.46 and a two-hundred day moving average price of $16.60.
Organon & Co. (NYSE:OGN - Get Free Report) last released its quarterly earnings results on Thursday, February 13th. The company reported $0.83 EPS for the quarter, missing analysts' consensus estimates of $0.92 by ($0.09). Organon & Co. had a return on equity of 431.62% and a net margin of 13.49%. The firm had revenue of $1.59 billion for the quarter, compared to analysts' expectations of $1.57 billion. Research analysts forecast that Organon & Co. will post 3.68 EPS for the current fiscal year.
Organon & Co. Announces Dividend
The firm also recently announced a quarterly dividend, which was paid on Thursday, March 13th. Stockholders of record on Monday, February 24th were paid a dividend of $0.28 per share. The ex-dividend date was Monday, February 24th. This represents a $1.12 dividend on an annualized basis and a dividend yield of 7.14%. Organon & Co.'s dividend payout ratio is 33.63%.
Analyst Upgrades and Downgrades
A number of analysts have issued reports on the company. Morgan Stanley reduced their price objective on Organon & Co. from $17.00 to $16.00 and set an "equal weight" rating on the stock in a research note on Friday, February 14th. TD Cowen raised shares of Organon & Co. to a "hold" rating in a research note on Wednesday, January 15th. Finally, Barclays dropped their price objective on shares of Organon & Co. from $26.00 to $24.00 and set an "overweight" rating for the company in a research note on Friday, February 14th. One research analyst has rated the stock with a sell rating, three have issued a hold rating, two have issued a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat, the company currently has an average rating of "Hold" and a consensus target price of $20.80.
Get Our Latest Report on Organon & Co.
Organon & Co. Company Profile
(
Free Report)
Organon & Co is a science based global pharmaceutical company, which develops and delivers innovative health solutions through a portfolio of prescription therapies within women's health, biosimilars and established brands. The company was founded on March 11, 2020, and is headquartered in Jersey City, NJ.
Recommended Stories
Before you consider Organon & Co., you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Organon & Co. wasn't on the list.
While Organon & Co. currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
